Taylor & Francis Group
Browse

Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients - Supplementary Figure 2

Download (89.18 kB)
figure
posted on 2022-01-06, 10:53 authored by Jianbo Zhu, Guangpeng Chen, Kai Niu, Yongdong Feng, Lijiao Xie, Si Qin, Zhongyu Wang, Jixi Li, Song Lang, Wenlei Zhuo, Zhengtang Chen, Jianguo Sun

Supplementary Figure 2. Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients

Grading of Radiation pulmonary fibrosis after radiotherapy

Funding

This study was supported by the National Key Research & Development Program (No. 2016YFC0106400), the National Natural Science Foundation of China (81773245, 81972858), the Technology Innovation and Application Development Project of Chongqing (cstccxljrc201910), and the Cultivation Program for Clinical Research Talents of Army Medical University (2018XLC1010).

History